Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:

A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01244490
• Other study ID #: SPD503-316
• Secondary ID: 2010-018579-12
• Status: Completed
• Phase: Phase 3
• Start date: January 17, 2011
• Est. completion date: May 1, 2013

Study information

• Verified date: June 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 338
• Est. completion date: May 1, 2013
• Est. primary completion date: May 1, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Male or female, aged 6 17 years at the time of consent/assent at Screening (Visit 1).

2. Subject's parent or legally authorised representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidance E6, and applicable regulations before completing any study related procedures at Screening (Visit 1).

3. Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD, combined sub-type, hyperactive/impulsive sub-type, or inattentive sub-type based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL).

4. Subject has a minimum ADHD-RS-IV total score of 32 at Baseline (Visit 2).

5. Subject has a minimum CGI-S score of 4 at Baseline (Visit 2).

6. Subject is functioning at an age-appropriate level intellectually, as judged by the Investigator.

7. Subject and parent/LAR understand, are willing, able, and likely to fully comply with the study procedures and restrictions defined in this protocol.

8. Subject is able to swallow intact tablets and capsules.

9. Subject who is a female of child-bearing potential (FOCP), defined as greater than or equal to 9 years of age or <9 years of age and is menarchal, must have a negative serum beta Human Chorionic Gonadotropin (hCG) pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol.

10. Subject has supine and standing blood pressure (BP) measurement within the 95th percentile for age, sex, and height

Exclusion Criteria:

1. Subject has a current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, co-morbid psychiatric diagnosis [except oppositional defiant disorder (ODD)], including any severe co-morbid Axis II disorders or severe Axis I disorders such as post traumatic stress disorder (PTSD), bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder (OCD), substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis or conduct disorder that, in the opinion of the Investigator, contraindicate treatment with SPD503 or STRATTERA or confound efficacy or safety assessments.

2. Subject is well-controlled on their current medication, with acceptable tolerability, and the parent/caregiver does not object to the current medication.

3. Subject has any condition or illness including a clinically significant abnormal Screening (Visit 1) laboratory values which, in the opinion of the Investigator, represents an inappropriate risk to the subject and/or could confound the interpretation of the study. Mild stable asthma treated without the use of beta-2 agonist is not exclusionary.

4. Subject has a known history or presence of structural cardiac abnormalities, cardiovascular or cerebrovascular disease, serious heart rhythm abnormalities, syncope, tachycardia, cardiac conduction problems (eg, clinically significant heart block or QT interval prolongation), exercise-related cardiac events including syncope and pre syncope, or clinically significant bradycardia.

5. Subject has a known family history of sudden cardiac death, ventricular arrhythmia, or QT prolongation.

6. Subjects with orthostatic hypotension or a known history of hypertension.

7. Subject has glaucoma.

8. Subject has clinically significant ECG findings as judged by the Investigator with consideration of the central ECG laboratory's interpretation.

9. Subject has a history of a seizure disorder (other than a single childhood febrile seizure occurring before the age of 3 years) or the presence of a serious tic disorder including Tourette's Syndrome.

10. Current use of any prohibited medication or other medications, including monoamine oxidase inhibitors, herbal supplements, that affect BP or heart rate potent CYP2D6 inhibitors, medications known to prolong the QT/QTc interval, medications that lower seizure threshold, pressor agents, beta-2 agonists, medications that affect noradrenaline, medications that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications [ie, antihistamines]) in violation of the protocol specified washout criteria at Baseline (Visit 2).

11. Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM-IV (with the exception of nicotine) within the last 6 months.

12. Subject has taken another investigational product within 30 days prior to Baseline (Visit 2).

13. Subject is significantly overweight based on Center for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts at the Screening (Visit 1). Significantly overweight is defined as a BMI >95th percentile.

14. Children aged 6 12 years with a body weight of less than 25kg or adolescents aged 13 17 years with a body weight of less than 34kg or greater than 91kg at Screening (Visit 1).

15. Subject has a known or suspected allergy, hypersensitivity, or clinically significant intolerance to guanfacine hydrochloride or atomoxetine hydrochloride, or any components found in SPD503 or STRATTERA.

16. Clinically important abnormality on drug and alcohol screen (excluding the subject's current ADHD stimulant if applicable) at Screening (Visit 1)

17. Subject is female and is pregnant or currently lactating.

18. Subject failed screening or was previously enrolled in this study.

19. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicide ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.

20. History of failure to respond to an adequate trial of an a2-agonist or atomoxetine hydrochloride for the treatment of ADHD (consisting of an appropriate dose and adequate duration of therapy in the opinion of the investigator).

21. Subjects with renal or hepatic insufficiency.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Hyperkinesis

Intervention

Drug:
• Extended-release Guanfacine Hydrochloride
Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
• Atomoxetine Hydrochloride
Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
• Placebo Comparator
Placebo

Locations

Country	Name	City	State
Austria	Medizinische Universitat Graz-Universitaklinik fur Kinder-und Jugendheilkunde	Graz
Austria	Institut für Psychosomatik	Wien
Canada	Dr Grazyna B. Jackiewicz, MD	Niagara Falls	Ontario
Canada	JPM Van Stralen Medicine Professional Corp.	Ottawa	Ontario
France	Centre HospitalierUniversitaire d'Amiens, Hoptial Nord	Amiens Cedex	Picardie
France	Centre Hospitalier Charles Perens - Service de Psychiatrie de l'Enfant et de l'Adolescent	Bordeaux
France	Centre Hospitalier des Pyrenees	Chartres
Germany	Praxis Dr. Andreas Mahler	Achim
Germany	Emovis GmbH	Berlin
Germany	Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden	Dresden
Germany	Praxisgemeinschaft Drs. Willem Geraets/Gabriele Lucassen	Dusseldorf
Germany	Praxis Dr. Walter Robert Otto	Fulda
Germany	Praxis Dr. Wolff	Hagen	Nordrhein-Westfalen
Germany	Praxis Dr. Friedrich Kaiser un Ingrid Marinesse	Hamburg
Germany	Institut fur Ganzheitiche Medzin und Wissenschaft GmbH	Huttenberg
Germany	Klinikum der Johannes-Guttenberg-Universitat Mainz	Mainz
Germany	Zentralinstitut fur Seelische Geseundheit Mannheim Klinik for Psuchiatrie und Psychotherapie des Kindes	Mannheim
Germany	Somni Bene GmbH - Institut für Medizinische Forschung und Schlafmedizin	Schwerin
Ireland	Department of Child and Adolescent Psychiatry	Dublin
Italy	IRCCS Stella Maris - U.O. Psichiatria e Psicofarmacologia Eta' Evolutiva	Pisa
Italy	Università Cattolica del Sacro Cuore	Rome
Italy	Ospedale Policlinico G.B.Rossi - Azienda Ospedaliera Universitaria Integrata Verona	Verona
Poland	Centrum Badan Klinicznych PI-House Sp. z o.o.	Gdansk	Pomorskie
Poland	NZOZ Gdan Skie Centrum Zdrowia	Gdansk
Poland	Gabinet Psychiatrii Doroslych, Dzieci i Mlodziezy, Miroslaw Dabkowski	Torun
Poland	Indywidualna Specjalistyczna Praktyka Lekarska Borys Gniot	Torun	Kujawsko-pomorskie
Poland	Samodzielny Publiczny Dzieciecy Szpital Kliniczny	Warszawa	Mazowieckie
Poland	Centrum Neuropsychiatrii Neuromed	Wroclaw	Dolnoslaskie
Romania	Spitalul Clinic de Psihiatrie "Prof. Dr. Alexandru Obregia"	Bucuresti
Romania	Spitalul Clinic de Urgenta Pentru Copii Cluj	Cluj Napoca	Cluj
Romania	Spitalul Clinic de Psihiatrie Socola	Iasi
Romania	Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu"	Timisoara	Timis
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Policlínica Guipuzkoa	Donostia-San Sebastián
Spain	Hospital Marítimo, (USMI-J)	Malaga
Spain	Hospital de Dia Infantil y Juvenil Dr Diego Guigou y Costa	Santa Cruz de Tenerife
Spain	Hospital Universitario Marques de Valdecilla	Santander
Spain	Mutua de Terrassa	Terrassa	Barcelona
Spain	Instituto Valenciano de Neurología Pediatrica	Valencia
Sweden	Drottning Silvias Barnsjukhus	Goteborg
Sweden	Barn och Ungdomsmedicin klinik Mölnlycke	Mölnlycke
Sweden	BUP mottagningen Varberg	Varberg
Ukraine	Regional Clinical Psychiatric Hospital	Donetsk
Ukraine	Municipal Institution "Institute of healthcare for children and adolescences NAMNU	Kharkiv
Ukraine	Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine	Kharkov	Kharkiv
Ukraine	Kherson Regional Psychiatric Hospital	Kherson
Ukraine	Lviv Regional Clinical Psychiatric Hospital	Lviv
Ukraine	Odesa Regional Psychoneurological Dispensary, Outpatient Dept	Odesa
Ukraine	O.F. Maltsev Poltava Regional Psychiatric Hospital	Poltava
Ukraine	Vinnytsia National Medical University - Vinnytsia Regional Psycho-Neurological Hospital	Vinnytsia
United Kingdom	Ashurt Child and Family Centre	Ashurst	Southampton
United Kingdom	James Paget University Hospital NHS Trust	Great Yarmouth	Norfolk
United Kingdom	Horsham Child and Adolescent Mental Health Services	Horsham
United Kingdom	Victoria Hospital	Kirkcaldy	Fife
United Kingdom	5 Boroughs Partnership NHS Trust	Wigan
United States	Atlanta Center for Medical Research	Atlanta	Georgia
United States	Innovis Health	Fargo	North Dakota
United States	NeuroScience Inc.	Herndon	Virginia
United States	Claghorn-Lesem Research Clinic	Houston	Texas
United States	R/D Clincial Research, Inc.	Lake Jackson	Texas
United States	Florida Clinical Research Center, LLC	Maitland	Florida
United States	Clinical Neuroscience Solutions, Inc.	Memphis	Tennessee
United States	University of Nebraska Medical Center, Dept. of Psychiatry	Omaha	Nebraska
United States	Psychiatric Associates	Overland Park	Kansas
United States	Rochester Center for Behavioral Medicine	Rochester Hills	Michigan
United States	Psychiatric Centers at San Diego, Feighner Research	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Countries where clinical trial is conducted

United States,  Austria,  Canada,  France,  Germany,  Ireland,  Italy,  Poland,  Romania,  Spain,  Sweden,  Ukraine,  United Kingdom, 

References & Publications (1)

Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorde — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)	The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores	Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF	The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF	The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Clinical Global Impression-Severity of Illness (CGI-S) - LOCF	CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF	HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF	The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF	The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF	The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF	The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF	The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF	The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF	The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF	The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.	Baseline and up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years
Secondary	Structure Side-Effect Questionnaire	The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking 'yes' on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.	Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years
Secondary	Columbia-Suicide Severity Rating Scale (C-SSRS)	C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.	Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years